Your browser doesn't support javascript.
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice.
Brandys, Pascal; Montagutelli, Xavier; Merenkova, Irena; Barut, Güliz T; Thiel, Volker; Schork, Nicholas J; Trüeb, Bettina; Conquet, Laurine; Deng, Aihua; Antanasijevic, Aleksandar; Lee, Hyun-Ku; Valière, Martine; Sindhu, Anoop; Singh, Gita; Herold, Jens.
  • Brandys P; Phylex BioSciences, Del Mar, CA, United States.
  • Montagutelli X; Institut Pasteur, Université Paris Cité, Mouse Genetics Laboratory, Paris, France.
  • Merenkova I; Phylex BioSciences, Del Mar, CA, United States.
  • Barut GT; Institute of Virology and Immunology, University of Bern, Mittelhäusern, Switzerland.
  • Thiel V; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Schork NJ; Institute of Virology and Immunology, University of Bern, Mittelhäusern, Switzerland.
  • Trüeb B; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Conquet L; Multidisciplinary Center for Infectious Diseases, University of Bern, Bern, Switzerland.
  • Deng A; Quantitative Medicine & Systems Biology Division, Translational Genomics Research Institute, Phoenix, AZ, United States.
  • Antanasijevic A; Institute of Virology and Immunology, University of Bern, Mittelhäusern, Switzerland.
  • Lee HK; Department of Infectious Diseases and Pathobiology, Vetsuisse Faculty, University of Bern, Bern, Switzerland.
  • Valière M; Institut Pasteur, Université Paris Cité, Mouse Genetics Laboratory, Paris, France.
  • Sindhu A; BTS Research, San Diego, CA, United States.
  • Singh G; Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA, United States.
  • Herold J; Abeomics, San Diego, CA, United States.
Front Immunol ; 13: 912898, 2022.
Article in English | MEDLINE | ID: covidwho-1957161
ABSTRACT
Two years into the COVID-19 pandemic there is still a need for vaccines to effectively control the spread of novel SARS-CoV-2 variants and associated cases of severe disease. Here we report a messenger RNA vaccine directly encoding for a nanoparticle displaying 60 receptor binding domains (RBDs) of SARS-CoV-2 that acts as a highly effective antigen. A construct encoding the RBD of the Delta variant elicits robust neutralizing antibody response, and also provides protective immunity against the Delta variant in a widely used transgenic mouse model. We ultimately find that the proposed mRNA RBD nanoparticle-based vaccine provides a flexible platform for rapid development and will likely be of great value in combatting current and future SARS-CoV-2 variants of concern.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 / MRNA Vaccines Type of study: Observational study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.912898

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Nanoparticles / COVID-19 / MRNA Vaccines Type of study: Observational study Topics: Vaccines / Variants Limits: Animals / Humans Language: English Journal: Front Immunol Year: 2022 Document Type: Article Affiliation country: Fimmu.2022.912898